UNLABELLED: The incidence of ventilator-associated pneumonia (VAP) by Acinetobacter spp (VAPA) is increasing and has high morbidity and mortality. It is imperative to identify risk factors to be able to use prevention policies. OBJECTIVE: The aim of this study was to identify specific risk factors for VAPA. DESIGN: Prospective cohort study. INTERVENTIONS: None. SETTING: Two medical-surgical intensive care units. MEASUREMENTS: During a period of 36 months, all patients with more than 48 hours on mechanical ventilation and suspected of having a VAP were enrolled. Only VAP with microbiological confirmation was analyzed. RESULTS: Two hundred eighteen consecutive patients with clinical suspicion of VAP were enrolled. One hundred twenty-five VAPs were confirmed by culture--46 by Acinetobacter spp and 79 by other pathogens. The 36 potential risk factors for Acinetobacter spp were analyzed by univariate analysis. Logistic regression identified previous use of ceftriaxone (relative risk, 5.1; 95% confidence interval, 1.47-17.82) and previous use of ciprofloxacin (relative risk, 9.1; 95% confidence interval, 2.29-36.63) as significant independent predictors for the development of VAPA. CONCLUSIONS: Previous use of ceftriaxone and ciprofloxacin are independent risk factors for the development of VAPA.
UNLABELLED: The incidence of ventilator-associated pneumonia (VAP) by Acinetobacter spp (VAPA) is increasing and has high morbidity and mortality. It is imperative to identify risk factors to be able to use prevention policies. OBJECTIVE: The aim of this study was to identify specific risk factors for VAPA. DESIGN: Prospective cohort study. INTERVENTIONS: None. SETTING: Two medical-surgical intensive care units. MEASUREMENTS: During a period of 36 months, all patients with more than 48 hours on mechanical ventilation and suspected of having a VAP were enrolled. Only VAP with microbiological confirmation was analyzed. RESULTS: Two hundred eighteen consecutive patients with clinical suspicion of VAP were enrolled. One hundred twenty-five VAPs were confirmed by culture--46 by Acinetobacter spp and 79 by other pathogens. The 36 potential risk factors for Acinetobacter spp were analyzed by univariate analysis. Logistic regression identified previous use of ceftriaxone (relative risk, 5.1; 95% confidence interval, 1.47-17.82) and previous use of ciprofloxacin (relative risk, 9.1; 95% confidence interval, 2.29-36.63) as significant independent predictors for the development of VAPA. CONCLUSIONS: Previous use of ceftriaxone and ciprofloxacin are independent risk factors for the development of VAPA.
Authors: Thabit Alotaibi; Abdulrhman Abuhaimed; Mohammed Alshahrani; Ahmed Albdelhady; Yousef Almubarak; Osama Almasari Journal: SAGE Open Med Date: 2021-03-15
Authors: Julio C Medina-Presentado; Alvaro Margolis; Lucia Teixeira; Leticia Lorier; Ana C Gales; Graciela Pérez-Sartori; Maura S Oliveira; Verónica Seija; Daniela Paciel; Rafael Vignoli; Silvia Guerra; Henry Albornoz; Zaida Arteta; Antonio Lopez-Arredondo; Sofía García Journal: Braz J Infect Dis Date: 2016-12-03 Impact factor: 3.257